Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cost of Revenue	0.79	-	-	-	-	-
Gross Profit	3.15	-	-	-	-	-
Selling, General & Admin	31.46	29.37	30.09	21.91	15.66	11.29
Depreciation & Amortization Expenses	0.57	-	-	-	-	-
Research & Development	8.63	9.16	11.91	14.82	17.66	12.24
Total Operating Expenses	40.66	38.53	42	36.73	33.32	23.53
Operating Income	-37.51	-38.53	-42	-36.73	-33.32	-23.53
Interest Income	0.13	0.11	0.76	1.18	0.25	0.26
Interest Expense	-0.42	-0.27	-	-	-	-0.01
Other Non-Operating Income (Expense)	-	-	2.39	3.59	-	0.23
Total Non-Operating Income (Expense)	-0.29	-0.16	3.15	4.77	0.25	0.48
Pretax Income	-37.8	-38.68	-38.85	-31.97	-33.06	-23.05
Provision for Income Taxes	1.06	1.06	0.58	0.58	0.58	-
Net Income	-35.89	-37.43	-40.19	-33.69	-33.64	-24.51
Minority Interest in Earnings	-2.97	-2.31	-0.29	-	-	-
Net Income Attributable to Preferred Dividends	-	-	-1.05	-1.15	-	1.45
Net Income to Common	-35.89	-37.43	-40.19	-33.69	-33.64	-24.51
Shares Outstanding (Basic)	15	11	7	6	6	4
Shares Outstanding (Diluted)	15	11	7	6	6	4
Shares Change (YoY)	107.83%	64.49%	11.16%	3.57%	34.52%	177.28%
EPS (Basic)	-2.56	-3.38	-5.97	-5.57	-5.75	-5.75
EPS (Diluted)	-2.56	-3.38	-5.97	-5.57	-5.75	-5.75
Shares Outstanding	22.38	18.07	7.25	6.35	5.85	5.84
Free Cash Flow	-34.84	-26.55	-28.2	-29.06	-28.36	-24.26
Free Cash Flow Per Share	-2.39	-2.40	-4.19	-4.80	-4.85	-5.58
EBITDA	-36.79	-38.31	-41.79	-36.54	-33.14	-23.37
EBIT	-37.51	-38.53	-42	-36.73	-33.32	-23.53
Effective Tax Rate	-2.80%	-2.73%	-1.48%	-1.80%	-1.74%	0.00%

Updated Feb 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q